Marinus Pharmaceuticals, Inc. (MRNS)
NASDAQ: MRNS · Real-Time Price · USD
0.230
-0.009 (-3.56%)
At close: Dec 20, 2024, 4:00 PM
0.233
+0.003 (1.39%)
After-hours: Dec 20, 2024, 5:36 PM EST
Marinus Pharmaceuticals Revenue
Marinus Pharmaceuticals had revenue of $8.54M in the quarter ending September 30, 2024, with 16.39% growth. This brings the company's revenue in the last twelve months to $31.47M, up 1.63% year-over-year. In the year 2023, Marinus Pharmaceuticals had annual revenue of $30.99M with 21.63% growth.
Revenue (ttm)
$31.47M
Revenue Growth
+1.63%
P/S Ratio
0.42
Revenue / Employee
$189,554
Employees
166
Market Cap
12.69M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cosmos Health | 56.04M |
STRATA Skin Sciences | 32.68M |
Ekso Bionics Holdings | 17.68M |
Sol-Gel Technologies | 11.71M |
Aspira Women's Health | 8.96M |
TherapeuticsMD | 1.60M |
Eterna Therapeutics | 598.00K |
AIM ImmunoTech | 190.00K |
MRNS News
- 5 weeks ago - Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - Business Wire
- 2 months ago - Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives - Business Wire
- 2 months ago - Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting - Business Wire
- 2 months ago - 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity - Benzinga
- 2 months ago - Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens - Business Wire
- 2 months ago - Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting - Business Wire
- 2 months ago - Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 2 months ago - Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech? - Benzinga